Pakistan Import Permits, Import NOC and PSW Clearance for Medical Devices
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Importing devices into Pakistan is a “documents + channel” two-layer structure: the document layer is the Import Permit and the per-shipment import No Objection Certificate (Import NOC); the channel layer is the Pakistan Single Window (PSW). According to DRAP letter No. 6-14/2025DDQA(VII)-0002, issued on 16 October 2026 and published on 17 October (signed by the Deputy Director of the QA Division, Ishtaiq Shafiq, endorsed by the DRAP Chief Executive Officer, and addressed to HDAP and PEMDA): importers who are recordable in PSW must submit through PSW; OIES is open only during the transition period to applicants who cannot use PSW because of data update issues.
The structural point behind the letter is that importation now runs on two tracks at once: the regulatory track, where permits and NOCs are granted, and the customs channel, where the declarations physically move. Aligning the two tracks is an operational task. An importer whose permit file is perfect but whose PSW and DRAP system records are stale will still watch a consignment stop at the port, because the channel layer cannot see what the document layer does not show. The practical remedy is to treat the system record as a living compliance object with its own maintenance schedule, refreshed at every certificate event, rather than as a one-time registration formality.
2. Legal basis
The table below sets out the sources governing who may import, under what permit, through which channel, and with what data obligations.
| Subject | Legal source | Provision / Reference |
| Importation handled by the licensed importer | Medical Devices Rules, 2017 | Rule 14(1)(b) |
| Import permit | Same rules, Schedule C permit entries | Rule 63 |
| Arrival notification | Form-11 | MDR 2017 |
| Import channel: PSW | DRAP letter No. 6-14/2025DDQA(VII)-0002, issued on 2026-10-16 | DRAP letter |
| Transitional arrangement: OIES | Same letter (only where PSW is unavailable) | DRAP letter |
| Data update obligation | Importers must complete the establishment licence and product registration information in the DRAP device licensing and registration system | DRAP letter |
Note that the letter is an administrative instruction about channels and data rather than a new fee or a new permit: the underlying permits and their fees remain governed by the Medical Devices Rules, 2017 and Schedule C, while the letter determines where and how the import process is executed. For planning purposes the letter should be read alongside the permit provisions: the permit answers the regulatory question of eligibility, and the letter answers the operational question of routing and data readiness.
3. Expert insights
Insight 1: the point of this letter is not the system change but data completeness. The letter also requires all importers to complete the data updates in the DRAP device licensing and registration system, including the establishment licence and product enlistment/registration information. This means that even when product registration is finished, importation still cannot proceed if the data in the system has not been synchronised. The regulator’s view has shifted from paper certificates to system records, and the system is now the operative truth at the port. Importers should audit their own records in the DRAP system the way they audit their certificates, because a mismatch between the two is no longer a clerical detail but a blocker. A quarterly self-check against the system record is proportionate to the risk and can be delegated to a single named owner once the routine is set up.
Insight 2: the text of the letter sets no explicit deadline for the transition period. We confirmed this point specifically during verification — the body of the letter does not state a specific sunset date for the transition. In practice, preparations should follow the logic of “PSW as the main channel, OIES as the exception”, and the data updates should be completed as soon as possible rather than relying on the transitional arrangement. An undefined transition is, in operational terms, a transition that can close at any time, and building a supply plan on the continued availability of the exception would be imprudent.
Insight 3: the import permit is a standing 5-year document, while the NOC is per-shipment. The two are not substitutes: the permit answers whether importation is possible in general, and the NOC answers whether this particular shipment can enter. Production and shipping plans should be paced around the NOC processing rhythm, not the permit validity period. Because the NOC operates at the level of each consignment, its document set travels with the shipment and must match the invoice, packing list, and certificate exactly, which is why the reconciliation work belongs before departure rather than at the port. Each NOC cycle should also feed its own lessons back into the timetable, since actual processing times observed over successive shipments are the best basis for planning the next ones.
4. Practical recommendations
What GRZAN delivers at the import stage is an “import three-piece set”: an import permit status table (document number, validity, coverage), a product-and-system data consistency check table (comparing the portal records against the certificates item by item), and a per-shipment NOC processing timetable. We particularly stress that the data reconciliation must be completed before the first shipment — once this kind of problem is exposed at the port, what is lost is the demurrage cost of an entire container. The three-piece set is deliberately simple enough to be maintained by the client’s own team after handover, and we recommend refreshing the consistency check table every time a certificate is renewed, varied, or newly issued, so that the system records never drift away from the paper file. The three documents together also shorten the conversation with any freight forwarder or customs broker, because every question the broker asks is answered by one of the three tables.
5. Verification checklist
- □ Valid import permit held (validity of 5 years)
- □ Establishment licence information updated in the DRAP device licensing and registration system
- □ Product enlistment/registration information updated in the system
- □ Confirmed that the importer is recordable in PSW
- □ Import NOC processing scheduled by shipment
- □ Arrival notification (Form-11) and other clearance materials prepared
Regulatory information verified as of 28 October 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us